Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Apogee Therapeutics, Inc. Common Stock (APGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: APGE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $93.88
Year Target Price $93.88
| 9 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.53B USD | Price to earnings Ratio - | 1Y Target Price 93.88 |
Price to earnings Ratio - | 1Y Target Price 93.88 | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 26.20 - 63.50 | Updated Date 06/29/2025 |
52 Weeks Range 26.20 - 63.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.65% | Return on Equity (TTM) -27.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2030423955 | Price to Sales(TTM) - |
Enterprise Value 2030423955 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44826000 | Shares Floating 37591864 |
Shares Outstanding 44826000 | Shares Floating 37591864 | ||
Percent Insiders 7.62 | Percent Institutions 137.72 |
Analyst Ratings
Rating 5 | Target Price 93.88 | Buy - | Strong Buy 9 |
Buy - | Strong Buy 9 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics, Inc. is a biotechnology company focused on developing differentiated biologics for the treatment of inflammatory and immunological diseases. It was founded in 2020 and went public in 2023. Its focus is on creating innovative therapies for diseases with high unmet needs.
Core Business Areas
- Biologics Development: Apogee develops monoclonal antibody therapies targeting specific inflammatory pathways.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Research and Discovery: Apogee engages in research to identify and validate new therapeutic targets.
Leadership and Structure
The leadership team consists of experienced biotech executives with expertise in drug development. The organizational structure is typical of a biotech company, with departments focused on research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- APG777: APG777 is Apogee's lead program, a subcutaneous antibody targeting IL-23 for the treatment of inflammatory bowel disease (IBD). It is currently in clinical development. Competing therapies include Stelara (JNJ), Skyrizi (ABBV), and Entyvio (TAK). No revenue or market share data currently available, as this is an investigational drug.
- APG808: APG808 is a subcutaneous antibody targeting IL-4Ru03b1, for the treatment of atopic dermatitis and asthma. It is currently in clinical development. Competing therapies include Dupixent (REGN/SNY) . No revenue or market share data currently available, as this is an investigational drug.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long development timelines, and regulatory scrutiny. It's highly competitive and driven by innovation.
Positioning
Apogee Therapeutics is positioned as an innovative player focused on developing differentiated biologics for inflammatory and immunological diseases. Its competitive advantage lies in its expertise in antibody engineering and targeted therapies.
Total Addressable Market (TAM)
The TAM for IBD and atopic dermatitis is estimated to be billions of dollars. Apogee is positioned to capture a portion of this market with its novel therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Experienced management team
- Strong financial backing
- Promising preclinical and clinical data
Weaknesses
- Early-stage company
- Dependence on clinical trial outcomes
- High cash burn rate
- Limited product pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- FDA approval of its drug candidates
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- TAK
- REGN
- SNY
Competitive Landscape
Apogee faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Apogee's advantage lies in its differentiated therapies and focus on specific inflammatory pathways.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is relatively new. Growth is measured by progress in clinical trials and expansion of the pipeline.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates. Analyst estimates vary widely and are subject to change based on clinical trial results. Projections are subject to change based on clinical trial outcomes.
Recent Initiatives: Recent initiatives include advancing APG777 and APG808 through clinical trials, expanding its research and development capabilities, and exploring partnerships.
Summary
Apogee Therapeutics is a promising early-stage biotech company focused on developing innovative therapies for inflammatory and immunological diseases. Its success hinges on positive clinical trial results and successful commercialization. The company faces significant competition and risks associated with drug development, but has strong financial backing and an experienced management team. Continued clinical progress will be important for share appreciation and industry acceptance. The company has a lot of promise but much more progress is needed before being seen as a serious competitor in the space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on your own research and consultation with a financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 | |||
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.